| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Reinhold Tacke, Friedrich Popp, Barbara Müller, Bastian Theis, Christian Burschka, Alexandra Hamacher, Matthias U Kassack, Dirk Schepmann, Bernhard Wünsch, Ulrik Jurva, Eric Wellne. Sila-haloperidol, a silicon analogue of the dopamine (D2) receptor antagonist haloperidol: synthesis, pharmacological properties, and metabolic fate. ChemMedChem. vol 3. issue 1. 2008-07-30. PMID:18022977. |
sila-haloperidol, a silicon analogue of the dopamine (d2) receptor antagonist haloperidol: synthesis, pharmacological properties, and metabolic fate. |
2008-07-30 |
2023-08-12 |
human |
| Reinhold Tacke, Friedrich Popp, Barbara Müller, Bastian Theis, Christian Burschka, Alexandra Hamacher, Matthias U Kassack, Dirk Schepmann, Bernhard Wünsch, Ulrik Jurva, Eric Wellne. Sila-haloperidol, a silicon analogue of the dopamine (D2) receptor antagonist haloperidol: synthesis, pharmacological properties, and metabolic fate. ChemMedChem. vol 3. issue 1. 2008-07-30. PMID:18022977. |
haloperidol (1 a), a dopamine (d(2)) receptor antagonist, is in clinical use as an antipsychotic agent. |
2008-07-30 |
2023-08-12 |
human |
| Paola Devoto, Giovanna Flore, Pierluigi Saba, M Paola Castelli, A Paola Piras, William Luesu, M Cristina Viaggi, M Grazia Ennas, Gian Luigi Gess. 6-Hydroxydopamine lesion in the ventral tegmental area fails to reduce extracellular dopamine in the cerebral cortex. Journal of neuroscience research. vol 86. issue 7. 2008-07-08. PMID:18189323. |
haloperidol failed to modify extracellular dopamine in either cortex but increased it in the nucleus accumbens, such an increase being greatly reduced in the denervated side. |
2008-07-08 |
2023-08-12 |
rat |
| Jesus Bertran-Gonzalez, Clémentine Bosch, Matthieu Maroteaux, Miriam Matamales, Denis Hervé, Emmanuel Valjent, Jean-Antoine Giraul. Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 28. issue 22. 2008-07-01. PMID:18509028. |
opposing patterns of signaling activation in dopamine d1 and d2 receptor-expressing striatal neurons in response to cocaine and haloperidol. |
2008-07-01 |
2023-08-12 |
mouse |
| N L M Quintão, J Ferreira, A Beirith, M M Campos, J B Calixt. Evaluation of the effects of the herbal product Catuama in inflammatory and neuropathic models of nociception in rats. Phytomedicine : international journal of phytotherapy and phytopharmacology. vol 15. issue 4. 2008-06-30. PMID:17482443. |
of high interest, the antinociceptive effects of catuama in the lps model were reversed significantly by the non-selective dopamine antagonist haloperidol, but not by serotonin methysergide or adrenergic yohimbine receptor antagonists. |
2008-06-30 |
2023-08-12 |
rat |
| Ingo Vernaleken, Yoshitaka Kumakura, Hans-Georg Buchholz, Thomas Siessmeier, Ralf-Dieter Hilgers, Peter Bartenstein, Paul Cumming, Gerhard Gründe. Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects. NeuroImage. vol 40. issue 3. 2008-06-17. PMID:18262797. |
we conclude that the initial increase of [(18)f]fluorodopamine turnover after acute haloperidol challenge is associated with an over-stimulation in individuals with initially more pharmacologically responsive dopamine systems, but optimizes cognitive performance in those with lower normal fdopa utilization at baseline. |
2008-06-17 |
2023-08-12 |
human |
| Shinobu Ito, Tomohisa Mori, Toshiko Sawaguch. Dopamine-independent psychostimulant activity of a delta-agonist. Behavioural pharmacology. vol 19. issue 2. 2008-06-17. PMID:18332675. |
although haloperidol (dopamine d2-receptor antagonist) did not affect snc80-induced hyperactivity, it inhibited morphine-induced hyperlocomotion. |
2008-06-17 |
2023-08-12 |
mouse |
| Philip Seema. Dopamine D2(High) receptors moderately elevated by sertindole. Synapse (New York, N.Y.). vol 62. issue 5. 2008-06-03. PMID:18293356. |
although the findings suggest that rats or patients treated with sertindole might exhibit behavioral dopamine supersensitivity, the drug-induced increase in d2(high) receptors was less than that previously found with haloperidol. |
2008-06-03 |
2023-08-12 |
rat |
| L N Markova, T V Ostroumova, M G Akimov, V V Bezuglo. [N-arachidonoyl dopamine is a possible factor of the rate of tentacle formation in freshwater hydra]. Ontogenez. vol 39. issue 1. 2008-06-03. PMID:18409382. |
the effect of n-arachidonoyl dopamine, haloperidol, and their mixture on the rate of tentacle formation was studied during regeneration of the gastral and basal fragments of freshwater hydra. |
2008-06-03 |
2023-08-12 |
Not clear |
| Mahendra Bishnoi, Kanwaljit Chopra, Shrinivas K Kulkarn. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid. Progress in neuro-psychopharmacology & biological psychiatry. vol 32. issue 2. 2008-05-30. PMID:17988775. |
further, chronic administration of haloperidol resulted in significant decrease in dopamine levels in rat striatum homogenates and increase in catecholamine metabolite levels. |
2008-05-30 |
2023-08-12 |
rat |
| Mahendra Bishnoi, Kanwaljit Chopra, Shrinivas K Kulkarn. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid. Progress in neuro-psychopharmacology & biological psychiatry. vol 32. issue 2. 2008-05-30. PMID:17988775. |
coadministration of progesterone also reversed the decrease in dopamine levels induced by chronic haloperidol treatment, an effect which was again reversed by pre treatment with finasteride. |
2008-05-30 |
2023-08-12 |
rat |
| Mahendra Bishnoi, Kanwaljit Chopra, Shrinivas K Kulkarn. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Pharmacology, biochemistry, and behavior. vol 88. issue 4. 2008-05-08. PMID:18022680. |
on chronic administration of haloperidol, there was a decrease in turnover of dopamine, serotonin and norepinephrine in both cortical and subcortical regions which was again dose-dependently reversed by treatment with curcumin. |
2008-05-08 |
2023-08-12 |
rat |
| Susanne Nikolaus, Rolf Larisch, Markus Beu, Christina Antke, Konstantin Kley, Farhad Forutan, Andreas Wirrwar, Hans-Wilhelm Mülle. Investigating the dopaminergic synapse in vivo. II. Molecular imaging studies in small laboratory animals. Reviews in the neurosciences. vol 18. issue 6. 2008-05-02. PMID:18330213. |
finally, preliminary results yielded the first evidence that acute pplication of haloperidol might induce a reduction of dopamine transporter binding, indicating an enhancement of dopamine release into the synaptic cleft. |
2008-05-02 |
2023-08-12 |
mouse |
| C Tomasetti, C Dell'Aversano, F Iasevoli, A de Bartolomei. Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action. Neuroscience. vol 150. issue 1. 2008-03-28. PMID:17916411. |
animals were treated with the typical antipsychotic haloperidol 0.8 mg/kg, the atypical antipsychotic clozapine 15 mg/kg, the dopamine partial agonist aripiprazole 12 mg/kg and 30 mg/kg and the dopamine transporter inhibitor gbr12909 30 mg/kg in acute and chronic paradigms. |
2008-03-28 |
2023-08-12 |
rat |
| Y Chertkow, O Weinreb, M B H Youdim, H Silve. Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment. Journal of neural transmission (Vienna, Austria : 1996). vol 114. issue 11. 2008-03-11. PMID:17576515. |
dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment. |
2008-03-11 |
2023-08-12 |
rat |
| Y Chertkow, O Weinreb, M B H Youdim, H Silve. Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment. Journal of neural transmission (Vienna, Austria : 1996). vol 114. issue 11. 2008-03-11. PMID:17576515. |
we studied dopamine and serotonin metabolism in different rat brain areas at 1.5 and 24 h after the last dosage of chronic treatment (30 days), with haloperidol plus fluvoxamine, each drug alone, and clozapine. |
2008-03-11 |
2023-08-12 |
rat |
| Y Chertkow, O Weinreb, M B H Youdim, H Silve. Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment. Journal of neural transmission (Vienna, Austria : 1996). vol 114. issue 11. 2008-03-11. PMID:17576515. |
haloperidol-fluvoxamine combination, haloperidol, and clozapine treatments increased striatal and frontal cortex dopamine turnover and reduced striatal tyrosine hydroxylase activity at 1.5 h. at 24 h both dopamine turnover and tyrosine hydroxylase activity were reduced. |
2008-03-11 |
2023-08-12 |
rat |
| Y Chertkow, O Weinreb, M B H Youdim, H Silve. Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment. Journal of neural transmission (Vienna, Austria : 1996). vol 114. issue 11. 2008-03-11. PMID:17576515. |
thus, in chronically treated animals, release of striatal dopamine increases following a drug pulse and returns to baseline by 24 h. serotonin and 5-hydroxyindoleacetic acid concentrations were decreased at 1.5 h in haloperidol-fluvoxamine and clozapine groups and returned to normal levels by 24 h. a limited behavioral assessment showed that treatment with haloperidol plus fluvoxamine reduced motor activity compared to haloperidol, and increased sniffing compared to haloperidol, fluvoxamine and clozapine. |
2008-03-11 |
2023-08-12 |
rat |
| Kurt Rasmussen, Mei-Ann Hsu, Stephen Noone, Bryan G Johnson, Linda K Thompson, Susan K Hemrick-Lueck. The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms. Schizophrenia bulletin. vol 33. issue 6. 2008-02-27. PMID:17660489. |
we have previously shown that the orexin-1 antagonist sb-334867 blocks the electrophysiological effects of haloperidol and olanzapine on the activity of a9 and a10 dopamine neurons. |
2008-02-27 |
2023-08-12 |
Not clear |
| Vera Bubenikova-Valesova, Ales Stuchlik, Jan Svoboda, Jan Bures, Karel Vale. Risperidone and ritanserin but not haloperidol block effect of dizocilpine on the active allothetic place avoidance task. Proceedings of the National Academy of Sciences of the United States of America. vol 105. issue 3. 2008-02-12. PMID:18195350. |
the aim of the present work was to establish the effect of the 5-ht2a/2c receptor antagonist ritanserin (2.5 or 5 mg/kg), the dopamine d2 antagonist haloperidol (0.1 or 1 mg/kg), and the atypical antipsychotic risperidone (0.1 mg/kg or 1 mg/kg), which is an antagonist of both 5-ht2a/2c and d2 receptors, on cognitive deficit induced by subchronic administration of dizocilpine (mk-801, 0.1 mg/kg). |
2008-02-12 |
2023-08-12 |
rat |